ID: MRFR/Pharma/3964-HCR | | Region: Global | 85 pages
Moebius syndrome is a rare neurological condition characterized by paralysis of multiple cranial nerves, and most often the abducens and facial nerves. Signs and symptoms of Moebius include paralysis of the facial muscles, swallowing and choking problems, crossed eyes, bone abnormalities in the hands, speech difficulties, high or cleft palate, excessive drooling, and various others. As per the National Center for Advancing Translational Sciences, abnormality of the voice, masklike facies, Bell's palsy, feeding difficulties in infancy, and open mouth commonly occur in 80%-99% cases of Moebius syndrome.
According to the U.S National Library of Medicine, Moebius syndrome affects 1 in 50,000 to 1 in 500,000 newborns. It also mentions that the affected individuals lack facial expressions i.e. they cannot smile, or raise their eyebrows.
It is noted that growing public awareness and technological advancements are the key factors driving the Moebius syndrome market. On the technology front, various surgical options have been used for an effective management of symptoms associated with Moebius syndrome such as facial nerve grafting, facial nerve decompression, transposition of the temporalis muscle, and others.
Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Moebius syndrome market. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and the hospital care accounted for a share of 32.3%.
Despite these drivers, there are some issues associated with Moebius syndrome market. The complications associated with the available treatments, infections, and injuries caused by surgical devices, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.
It is estimated that the Moebius syndrome market is expected to grow at a CAGR of 6.5% during the forecast period of 2017-2023.
Some of key the players in the global moebius syndrome market are Alcon Laboratories, Inc, All Vascular, Pty Ltd., Aspen Surgical Products, Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, Conmed Corporation, Gray Surgical, Johnson & Johnson Services, Inc., Medtronic, Olympus Corporation, Smith & Nephew plc, TransEnterix Surgical, Inc., Zimmer Biomet Holdings, Inc., and others.
Sources: Annual reports, Press release, White paper, and Company presentation
The global Moebius syndrome market is segmented on the basis of type, treatment, and end user.
On the basis of the type, the market is classified as Group I, Group II, Group III, and Group IV.
On the basis of the treatment, the market is classified as surgery, temporalis transfer, parotidectomy, physical therapy, occupational therapy, speech therapy, splints, prosthesis, braces, and others. The surgery segment is further classified into eyelid surgery, ponseti method, hand surgery, tracheotomy, and others.
On the basis of the end user, the market is segmented into medical device companies, hospitals & clinics, academic & research institutes, and others.
The Americas dominate the Moebius syndrome market owing to the rising awareness among the population coupled with and high healthcare expenditure.
Europe holds the second position in the Moebius syndrome market. It is expected that the support provided by the government authorities for research & development and initiatives taken to improve the reimbursement policies in healthcare is likely to drive the European market.
Asia Pacific is the fastest growing Moebius syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure in Australia was USD 170.4 billion, which is recorded to be 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.
Frequently Asked Questions (FAQ) :
moebius syndrome market is projected to grow at a 6.5% CAGR between 2017-2023.
The Americas is expected to dominate the moebius syndrome market.
Unmet medical needs and favorable reimbursement policies are the key factors driving the moebius syndrome market growth.
Poor healthcare system may limit the moebius syndrome market growth.
Major end users of the moebius syndrome market include academic and research institutes, hospitals and clinics, and medical device companies.